Tepoditamab

N/A

Report date: 2026/03/19 17:23:56

Base Information

Drug NameTepoditamab
Drug Alias NameMCLA-117
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanBiologics > T cell engagers
Mechanisms of ActionT lymphocytes stimulantsC-Type lectin domain family 12 member A modulatorsCD3 T-cell engagers
TargetsT cell surface glycoprotein CD3C-Type lectin domain family 12 member A
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesNetherlands +[5] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesInstitute Gustave-RoussyPharmaceutical Research AssociatesMerus Nv +[5] 
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGustave Roussy InstituteMerus Nv
Active IndicationsN/A
Inactive IndicationsLeukemia, Myeloid, Acute

Other Information

ATC CodeN/A
Related LinksN/A